Key Highlights

  • Shares closed at $25.94 at last closing, down 2.52%.
  • Second-quarter 2026 Revenue was about $350.5 million, up roughly 5% and beating estimates, with Earnings Per Share and Net Income rising sharply and adjusted EBITDA and margins expanding.
  • The company cut its full-year revenue and adjusted-EBITDA guidance and guided the next quarter below expectations amid roughly flat sales volumes, and shares fell about 10% after the report.
  • Progyny provides fertility and family-building benefits, and increasingly broader women's health benefits, to employers.

Progyny (NASDAQ:PGNY) is a benefits-management company that provides fertility and family-building benefits, and increasingly broader women's health benefits, to employers, managing these programs for a large base of clients and covered lives. Shares closed at $25.94 at last closing, down 2.52%.

Its results depend on revenue growth, its client and covered-life additions, utilization of its benefits, and its guidance, so it is exposed to employer benefits Demand and member utilization trends.

Latest Developments

In its second-quarter 2026 results, Progyny reported revenue of about $350.5 million, up roughly 5% and beating estimates, with earnings per share and net income rising sharply and adjusted EBITDA and margins expanding, but it cut its full-year revenue and adjusted-EBITDA guidance and guided the next quarter below expectations amid roughly flat sales volumes, and the shares fell about 10% after the report. Investors should confirm the latest client and covered-life trends, utilization, and updated guidance directly from SEC filings, distinguishing the profitability improvement from the guidance cut and decelerating growth that drove the sell-off.

Financial and Business Position

Progyny's Investment case rests on its specialized fertility and family-building benefits business and its expanding margins and profitability, balanced against decelerating revenue growth, flat sales volumes, and guidance risk. Investors should watch revenue and its growth, client and covered-life trends, and guidance.

Stock-Market Context

PGNY shares closed at $25.94 at last closing, down 2.52%, extending the roughly 10% decline that followed the guidance cut. The stock trades on its growth and profitability, and while margins are improving, the guidance cut and flat volumes are why a genuine breakout would require reaccelerating growth alongside continued Margin gains.

What Investors Should Watch

Watch revenue and its growth, earnings and net income, adjusted EBITDA and margins, client and covered-life trends, utilization, and guidance. A reacceleration in revenue growth combined with continued margin expansion and stabilizing guidance would be needed for a durable move higher.